Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 10074928)

  • 1. Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells.
    Kraus A; Neff F; Behn M; Schuermann M; Muenkel K; Schlegel J
    Int J Cancer; 1999 Mar; 80(6):930-4. PubMed ID: 10074928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abundant expression of spliced HDM2 in Hodgkin lymphoma cells does not interfere with p14(ARF) and p53 binding.
    Stürzenhofecker B; Schlott T; Quentin T; Kube D; Jung W; Trümper L
    Leuk Lymphoma; 2003 Sep; 44(9):1587-96. PubMed ID: 14565663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative and aberrant splicing of MDM2 mRNA in human cancer.
    Bartel F; Taubert H; Harris LC
    Cancer Cell; 2002 Jul; 2(1):9-15. PubMed ID: 12150820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pathway regulating MDM2 protein degradation can be altered in human leukemic cells.
    Pan Y; Haines DS
    Cancer Res; 1999 May; 59(9):2064-7. PubMed ID: 10232588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer.
    Sigalas I; Calvert AH; Anderson JJ; Neal DE; Lunec J
    Nat Med; 1996 Aug; 2(8):912-7. PubMed ID: 8705862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
    Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
    Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation.
    Zaika A; Marchenko N; Moll UM
    J Biol Chem; 1999 Sep; 274(39):27474-80. PubMed ID: 10488081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms.
    Matsumoto R; Tada M; Nozaki M; Zhang CL; Sawamura Y; Abe H
    Cancer Res; 1998 Feb; 58(4):609-13. PubMed ID: 9485008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation.
    Okada Y; Osada M; Kurata S; Sato S; Aisaki K; Kageyama Y; Kihara K; Ikawa Y; Katoh I
    Exp Cell Res; 2002 Jun; 276(2):194-200. PubMed ID: 12027449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
    Landers JE; Cassel SL; George DL
    Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MDM2-p53 interaction.
    Moll UM; Petrenko O
    Mol Cancer Res; 2003 Dec; 1(14):1001-8. PubMed ID: 14707283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of p53 stability by Mdm2.
    Kubbutat MH; Jones SN; Vousden KH
    Nature; 1997 May; 387(6630):299-303. PubMed ID: 9153396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation.
    Jin Y; Lee H; Zeng SX; Dai MS; Lu H
    EMBO J; 2003 Dec; 22(23):6365-77. PubMed ID: 14633995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation.
    Zilfou JT; Hoffman WH; Sank M; George DL; Murphy M
    Mol Cell Biol; 2001 Jun; 21(12):3974-85. PubMed ID: 11359905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of p53 by Mdm2: fate is in the numbers.
    Shmueli A; Oren M
    Mol Cell; 2004 Jan; 13(1):4-5. PubMed ID: 14731389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypophosphorylation of Mdm2 augments p53 stability.
    Blattner C; Hay T; Meek DW; Lane DP
    Mol Cell Biol; 2002 Sep; 22(17):6170-82. PubMed ID: 12167711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
    Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
    Mol Cell Biol; 2000 Nov; 20(22):8458-67. PubMed ID: 11046142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.
    Sánchez-Beato M; Piris MA; Martínez-Montero JC; García JF; Villuendas R; García FJ; Orradre JL; Martínez P
    J Pathol; 1996 Sep; 180(1):58-64. PubMed ID: 8943816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of deletion-mutant epidermal growth factor receptor is associated with altered genotoxic stress-provoked p53 mRNA induction in a human glioblastoma cell line.
    Halatsch ME; Schmidt U; Bötefür IC; Holland JF; Ohnuma T
    Anticancer Res; 2001; 21(1A):189-95. PubMed ID: 11299733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.
    Brignone C; Bradley KE; Kisselev AF; Grossman SR
    Oncogene; 2004 May; 23(23):4121-9. PubMed ID: 15064742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.